Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0K0DB
|
||||
Former ID |
DNC001225
|
||||
Drug Name |
RO-25-6981
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Cancer pain [ICD9: 140-229, 338,780; ICD10:R52, G89] | Terminated | [1] | ||
Therapeutic Class |
Analgesics
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C22H29NO2
|
||||
Canonical SMILES |
CC(CN1CCC(CC1)CC2=CC=CC=C2)C(C3=CC=C(C=C3)O)O
|
||||
InChI |
1S/C22H29NO2/c1-17(22(25)20-7-9-21(24)10-8-20)16-23-13-11-19(12-14-23)15-18-5-3-2-4-6-18/h2-10,17,19,22,24-25H,11-16H2,1H3/t17-,22+/m0/s1
|
||||
InChIKey |
WVZSEUPGUDIELE-HTAPYJJXSA-N
|
||||
CAS Number |
CAS 169274-78-6
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Glutamate [NMDA] receptor subunit epsilon 2 | Target Info | Antagonist | [2] | |
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
cAMP signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Circadian entrainment | |||||
Long-term potentiation | |||||
Glutamatergic synapse | |||||
Dopaminergic synapse | |||||
Alzheimer's disease | |||||
Amyotrophic lateral sclerosis (ALS) | |||||
Huntington's disease | |||||
Cocaine addiction | |||||
Amphetamine addiction | |||||
Nicotine addiction | |||||
Alcoholism | |||||
Systemic lupus erythematosus | |||||
PANTHER Pathway | Huntington disease | ||||
Ionotropic glutamate receptor pathway | |||||
Metabotropic glutamate receptor group III pathway | |||||
Metabotropic glutamate receptor group I pathway | |||||
Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
Pathway Interaction Database | ErbB4 signaling events | ||||
Reelin signaling pathway | |||||
Reactome | EPHB-mediated forward signaling | ||||
Unblocking of NMDA receptor, glutamate binding and activation | |||||
CREB phosphorylation through the activation of CaMKII | |||||
Ras activation uopn Ca2+ infux through NMDA receptor | |||||
RAF/MAP kinase cascade | |||||
WikiPathways | Hypothetical Network for Drug Addiction | ||||
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
BDNF signaling pathway | |||||
References | |||||
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009657) | ||||
REF 2 | Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.